Since 2016 the UCT Mainz Clinician and Medical Scientist Program is integrated in the Mainz Research School of Translational Biomedicine (
TransMed). TransMed offers a training curriculum with maximum flexibility for both clinician and medical scientists. For all trainees, the TransMed program provides an individual curriculum with training modules for basic scientific skills including lab-based research rotations and transferable skills. All fellowships consist of a 2-3 year program (depending on the training level). The hosting institutions commit themselves to allow the fellows to dedicate at least 12 months protected time solely to research. All trainees at all stages experience dual mentoring by a clinician and a medical scientist. For women in science a specialized mentoring program is available (
MeMentUM) additionally. The UCT Mainz clinician scientist program to support motivated physicians dedicated to cancer research was established in close collaboration with TransMed and specialized oncology training sessions (oncology class, oncology lab seminar, interdisciplinary molecular- pathology-oncology seminar) have been set up. Further, the UCT Mainz strongly supports rotations of medical scientists in clinical trials units and oncology departments. Since 2016, 14 clinician scientists were funded by the UCT Mainz and participated in the UCT Mainz training program. In 2019, the UCT Mainz successfully applied for the
Else Kröner-Research College focusing on the pathogenesis and progression of liver cancer. The first of the now 16 Else Kröner-Research College fellows started their research in January 2020. Since 2023 the new
Else Kröner School for Medical Scientists “RNA-based therapeutic strategies in tumor immunology and immune-mediated diseases, TheRNAtics" builds a bridge between (basic) scientific and clinically active researchers with a view to modern RNA-based immune and cancer therapies. In 2024 the
Else Kröner Graduate School for Mecial Students "ImmunYoAge: The Immune System – Young versus Aged" will start.